RET and medullary thyroid gland carcinoma: This median DOR is comparable with the DOR observed in the overall MTC population (Retsevmo SmPC4), as well as in MTC patients with other mutations in extracellular cysteine-rich domain (CRD) of RET (Fig. 1A).